Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma is a research paper published in Journal for ImmunoTherapy of Cancer (2023). On theSindex it has a DataRank of 0.546. It has been cited 37 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.546
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: 3T32GM144273-03S1
Medical Scientist Training Program
National Institutes of Health
Grant: 5U01CA274276-03
Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity
National Institutes of Health
Grant: 3T32GM007753-41S1
Medical Scientist Training Program
National Institutes of Health
Grant: 1F32GM013039-01
MOLECULAR ANALYSIS OF THE YEAST HEAT SHOCK TRANSCRIPTION
National Institutes of Health
Grant: 5U01CA210171-04
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection
National Institutes of Health
Grant: 5P50CA127003-12
Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer
Fields of Study
Keywords
Sustainable Development Goals